Andrew is a member of our chemistry and materials patent teams.
He obtained an MSci (Hons) in Medicinal & Biological Chemistry at the University of Nottingham, completing his final year research project in the lab of Dr Robert Stockman on the use of chiral sulfinimines in flow. His third year of undergraduate studies was spent working at AstraZeneca in Mölndal, Sweden. He then completed a Ph.D. in organic chemistry at the University of Cambridge under the supervision of Prof. Matthew J. Gaunt working on C–H functionalisation and natural product synthesis. During his third year of postgraduate studies he gained further industrial experience after returning to AstraZeneca for three months.
Andrew joined Mewburn Ellis in 2015.